ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Impact ofFujita medical journal · 2025Article
- Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies.Blood advances · 2024Article
- Glycolysis-mTORC1 crosstalk drives proliferation of patient-derived endometrial cancer spheroid cells with ALDH activity.Cell death discovery · 2024Article
- Copper homeostasis and cuproptosis in gynecological cancers.Frontiers in cell and developmental biology · 2024Review
- PRMT3-Mediated Arginine Methylation of METTL14 Promotes Malignant Progression and Treatment Resistance in Endometrial Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Development and verification of a newly established cuproptosis-associated lncRNA model for predicting overall survival in uterine corpus endometrial carcinoma.Translational cancer research · 2023Article
- Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.Pharmaceutics · 2023Review
- Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma.Cancer science · 2022Article
- HepaCAM‑PIK3CA axis regulates the reprogramming of glutamine metabolism to inhibit prostate cancer cell proliferation.International journal of oncology · 2022Article
- The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in aFrontiers in oncology · 2022Article
- Collagen triple helix repeat containing 1 promotes endometrial cancer cell migration by activating the focal adhesion kinase signaling pathway.Experimental and therapeutic medicine · 2020Article
- Review
- Article
- Alteration of tumor associated neutrophils by PIK3CA expression in endometrial carcinoma from TCGA data.Journal of ovarian research · 2019Article
- Impact of p85α Alterations in Cancer.Biomolecules · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 4 countries.
Funding
Abstract
purposeAmplification of EXPERIMENTAL
designUCECs from 591 clinically annotated patients including 83 tumors with matching metastasis (
results
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.